At EBMT 2025, Dr. Luca Vago delivered a compelling presentation titled “Mechanisms of Leukemia Relapse after Allogeneic Transplantation: From Biology to Treatment (and Back).” His talk focused on the intricate…

At the 51st Annual Meeting of EBMT, Dr. Rawad Rihani from the King Hussein Cancer Center (Jordan) delivered an important presentation on the determinants and outcomes of graft failure (GF)…

At EBMT 2025, Dr. Rémy Duléry (Dana-Farber Cancer Institute) presented highly promising data on novel immunotherapeutic strategies for relapsed/refractory AML. While CD123-targeted CAR T-cell therapy has shown limited long-term survival…

At the opening plenary of EBMT 2025, Dr. Luca Vago (Italy) delivered a thought-provoking presentation on the biological complexity behind leukemia relapse after allogeneic hematopoietic cell transplantation (allo-HCT).

At the EBMT 2025 Congress, Dr. Alice Bertaina (Stanford University, USA) presented encouraging Phase Ia data on T-allo10 immunotherapy following TCRαβ-depleted hematopoietic stem cell transplantation (HSCT) in pediatric and young adult patients with hematologic malignancies.

At this year’s EBMT Congress in Florence, Prof. Gandhi Damaj (Hematology Institute, Normandy University, France) presented the latest recommendations from the EBMT Practice Harmonisation and Guidelines Committee on allogeneic hematopoietic cell transplantation (allo-HCT) in PTCL.

At EBMT 2025, Dr. Nicoletta Cieri (Dana-Farber Cancer Institute) delivered a forward-looking presentation exploring the prognostic potential of mHAg load in allogeneic hematopoietic cell transplantation (allo-HCT).Her findings suggest that systematic…

At EBMT 2025, Dr. Giorgia Battipaglia shared important findings from a multicenter study comparing post-transplant cyclophosphamide (PTCy) versus antithymocyte globulin (ATG) as GVHD prophylaxis in patients with relapsed/refractory AML undergoing…

At EBMT 2025, Dr. Edouard Forcade presented the results of a multicenter randomized trial comparing cyclosporine (CsA) alone versus CsA plus mycophenolate mofetil (MMF) in patients with intermediate-risk AML in…